Sage to run 3 new studies to save once-failed depression drug

Sage to run 3 new studies to save once-failed depression drug

Source: 
Fierce Biotech
snippet: 

Sage Therapeutics has plotted out how it plans to bounce back from the phase 3 failure of SAGE-217 in major depressive disorder. The strategy centers on three short-term studies Sage thinks may enable it to bring the GABA receptor positive allosteric modulator to market in multiple indications.